Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Oncology Research Laboratory, Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, 710061, China.
Curr Cancer Drug Targets. 2024;24(10):1031-1046. doi: 10.2174/0115680096277126240102060617.
Metastatic renal cell carcinoma (RCC) poses a huge challenge once it has become resistant to targeted therapy. Vasculogenic mimicry (VM) is a novel blood supply system formed by tumor cells that can circumvent molecular targeted therapies. As one of the herbal remedies, curcumin has been demonstrated to play antineoplastic effects in many different types of human cancers; however, its function and mechanism of targeting VM in RCC remains unknown.
Here, in the work, we explored the role of curcumin and its molecular mechanism in the regulation of VM formation in RCC.
RNA-sequencing analysis, immunoblotting, and immunohistochemistry were used to detect E Twenty Six-1(ETS-1), vascular endothelial Cadherin (VE-Cadherin), and matrix metallopeptidase 9 (MMP9) expressions in RCC cells and tissues. RNA sequencing was used to screen the differential expressed genes. Plasmid transfections were used to transiently knock down or overexpress ETS-1. VM formation was determined by tube formation assay and animal experiments. CD31-PAS double staining was used to label the VM channels in patients and xenograft samples.
Our results demonstrated that VM was positively correlated with RCC grades and stages using clinical patient samples. Curcumin inhibited VM formation in dose and time-dependent manner . Using RNA-sequencing analysis, we discovered ETS-1 as a potential transcriptional factor regulating VM formation. Knocking down or overexpression of ETS-1 decreased or increased the VM formation, respectively and regulated the expression of VE-Cadherin and MMP9. Curcumin could inhibit VM formation by suppressing ETS-1, VE-Cadherin, and MMP9 expression both and .
Our finding might indicate that curcumin could inhibit VM by regulating ETS-1, VE-Cadherin, and MMP9 expression in RCC cell lines. Curcumin could be considered as a potential anti-cancer compound by inhibiting VM in RCC progression.
转移性肾细胞癌(RCC)一旦对靶向治疗产生耐药性,就会带来巨大挑战。血管生成拟态(VM)是肿瘤细胞形成的一种新的血液供应系统,可以规避分子靶向治疗。姜黄素作为一种草药,已被证明在许多不同类型的人类癌症中具有抗肿瘤作用;然而,其在 RCC 中靶向 VM 的功能和机制尚不清楚。
本研究旨在探讨姜黄素在调节 RCC 中 VM 形成中的作用及其分子机制。
采用 RNA 测序分析、免疫印迹和免疫组织化学检测 RCC 细胞和组织中 ETS-1、血管内皮钙黏蛋白(VE-Cadherin)和基质金属蛋白酶 9(MMP9)的表达。采用 RNA 测序筛选差异表达基因。质粒转染用于瞬时敲低或过表达 ETS-1。采用管形成试验和动物实验检测 VM 形成。CD31-PAS 双重染色用于标记患者和异种移植样本中的 VM 通道。
本研究结果表明,临床患者样本中 VM 与 RCC 分级和分期呈正相关。姜黄素呈剂量和时间依赖性抑制 VM 形成。通过 RNA 测序分析,我们发现 ETS-1 是调节 VM 形成的潜在转录因子。敲低或过表达 ETS-1 分别降低或增加了 VM 的形成,并调节了 VE-Cadherin 和 MMP9 的表达。姜黄素通过抑制 ETS-1、VE-Cadherin 和 MMP9 的表达抑制 VM 的形成。
本研究结果表明,姜黄素可能通过调节 RCC 细胞系中的 ETS-1、VE-Cadherin 和 MMP9 表达来抑制 VM。姜黄素可能通过抑制 VM 来抑制 RCC 进展,被认为是一种有潜力的抗癌化合物。